Modifies provisions relating to the integrity of food products
HB 1653 would revise Missouri’s food, drug, and cosmetic laws to add new definitions and labeling rules focused on two specific technologies: cell-cultured meat and mRNA-based products used in food animals or crops. The bill defines “cell-cultured meat product” as meat grown from animal cells in a controlled environment and excludes it from the statutory definition of “meat.” It also defines “mRNA-based product” broadly to include vaccines, treatments, or substances using mRNA or other gene-therapy mechanisms in animals or plants used for human food.
The bill would prohibit the manufacture, processing, possession for sale, distribution, offering for sale, or sale of cell-cultured meat products for human consumption in Missouri, except for bona fide scientific research in accredited academic or government laboratories where the product is not sold or offered for consumption. It would also require disclosure on labels for meat, poultry, fish, or agricultural products derived from animals or plants exposed to an mRNA-based product or gene-therapy substance, unless the use is clearly disclosed in print at least as large as the ingredient list. Conventional, non-gene-altering vaccines or biologics traditionally used for animal health and approved under state or federal law would be exempt.
In addition to the new prohibitions and labeling rules, HB 1653 would amend Missouri’s existing misbranding and enforcement provisions. It gives the Department of Health and Senior Services, and in some cases the Department of Agriculture, authority to promulgate rules to implement the new requirements, including verification and inspection procedures, labeling standards, and coordination with USDA and FDA. The bill also authorizes administrative penalties of up to $10,000 per violation for certain misbranding and cell-cultured meat violations, while preserving existing misdemeanor penalties for violations of the food law.
The overall sentiment reflected in the bill text is strongly precautionary and protective of Missouri’s livestock industry, food supply integrity, and consumer transparency. The emergency clause underscores urgency and suggests the sponsor viewed the measure as necessary for immediate public health and economic protection. Because there are no committee transcripts or recorded votes in the provided context, there is no direct evidence of debate, but the structure of the bill indicates support for stricter state control over emerging food technologies.
The main point of contention is likely to be the bill’s broad restriction on cell-cultured meat and its mandatory disclosure regime for products associated with mRNA or gene-therapy exposure. Supporters would likely frame these provisions as transparency and biosecurity measures, while opponents may view them as anti-innovation, potentially burdensome to producers, and possibly preempted or complicated by federal food regulation. The bill also appears to create tension between state-level labeling requirements and existing federal standards by allowing Missouri to impose requirements beyond federal law in the targeted areas.
HB 1653 would amend Chapter 196 of the Missouri statutes governing food, drugs, devices, and cosmetics by adding definitions, prohibitions, labeling requirements, and enforcement authority related to cell-cultured meat and mRNA-based products. It would specifically exclude cell-cultured meat from the statutory definition of meat, prohibit its sale for human consumption, and require disclosure when food products come from animals or plants exposed to mRNA-based or gene-therapy substances. The bill also expands rulemaking authority for the Department of Health and Senior Services and the Department of Agriculture, and it authorizes administrative penalties for certain violations, thereby increasing state regulatory oversight of food labeling and product integrity.
The bill’s tone and stated emergency clause indicate a generally supportive, protective sentiment toward Missouri agriculture, livestock producers, and consumer disclosure. The measure is framed as an immediate response to perceived risks in the food supply and as a way to ensure transparency for consumers. No committee testimony or vote record was provided, so there is no documented opposition or bipartisan split in the supplied materials, but the bill’s restrictive approach suggests it would likely draw mixed reactions from agricultural, food-tech, and consumer-policy stakeholders.
The most notable contention is the bill’s categorical ban on cell-cultured meat sales in Missouri, which would directly affect alternative-protein companies, food manufacturers, distributors, and retailers. A second major issue is the required labeling of products derived from animals or plants exposed to mRNA-based products or gene-therapy substances, which could be disputed by producers as scientifically or operationally burdensome. The bill also raises questions about state versus federal authority because it authorizes Missouri agencies to impose requirements beyond federal law in these areas, potentially creating compliance and preemption concerns. Supporters are likely to be livestock and traditional agriculture interests; opponents are likely to include cultivated-meat developers, some food processors, and groups concerned about regulatory overreach.